Holen Sie sich die Stockscreener-App
0.7864
6.16%
-0.0516
Handel nachbörslich:
.81
0.0236
+3.00%
Schlusskurs vom Vortag:
$0.838
Offen:
$0.829
24-Stunden-Volumen:
247.76K
Relative Volume:
0.61
Marktkapitalisierung:
$6.86M
Einnahmen:
$6.74M
Nettoeinkommen (Verlust:
$-14.74M
KGV:
-0.3497
EPS:
-2.2491
Netto-Cashflow:
$-18.31M
1W Leistung:
-8.63%
1M Leistung:
-28.51%
6M Leistung:
-34.63%
1J Leistung:
-44.37%
1-Tages-Spanne:
$0.73
$0.8359
1-Wochen-Bereich:
$0.73
$0.8845
52-Wochen-Spanne:
$0.73
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.7864 | 7.31M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-07-29 | Eingeleitet | Aegis Capital | Buy |
| 2020-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2013-12-16 | Eingeleitet | Oppenheimer | Outperform |
Evogene Ltd Aktie (EVGN) Neueste Nachrichten
Evogene Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Evogene’s Q4 2025 highlights restructuring gains By Investing.com - Investing.com India
Evogene: Q4 Earnings Snapshot - KVUE
Evogene earnings missed by $0.20, revenue topped estimates - Investing.com India
Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul - TipRanks
EVOGENE ($EVGN) Releases Q4 2025 Earnings - Quiver Quantitative
Evogene Earnings Review: Q4 Summary - Benzinga
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
An Overview of Evogene's Earnings - Benzinga
Evogene Ltd expected to post a loss of 26 cents a shareEarnings Preview - TradingView
EVGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EVGN Should I Buy - Intellectia AI
Is Evogene Ltd. stock heavily shortedJuly 2025 Retail & Reliable Trade Execution Plans - mfd.ru
Evogene refocuses on AI drug discovery platform ChemPass By Investing.com - Investing.com India
Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets - The Globe and Mail
Evogene refocuses on AI drug discovery platform ChemPass - Investing.com
Evogene Releases CEO Letter to Shareholders - Finviz
Evogene substantially completed divestment of non-core subsidiaries - marketscreener.com
Evogene (EVGN) pivots to ChemPass AI and core health and ag markets - Stock Titan
Fund Flows: Does Evogene Ltd have consistent dividend growth2025 Market WrapUp & AI Based Trade Execution Alerts - baoquankhu1.vn
Winners Losers: Is ProShares Trust ProShares UltraShort Consumer Staples likely to announce a buybackWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
CEO Moves: Is Evogene Ltd in a consolidation phaseJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - baoquankhu1.vn
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release – Company Announcement - Financial Times
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release - Barchart.com
Evogene and QUT partner on AI-based cancer therapies - Pharmaceutical Business review -
Ideas Watch: Is Huntington Ingalls Industries Inc a good stock for dollar cost averaging2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
New AI-led push targets lung cancers that resist chemo and drugs - Stock Titan
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics - StreetInsider
Will Evogene Ltd. stock hit new highs in YEARBear Alert & Accurate Entry/Exit Alerts - mfd.ru
Why did EVGN shares drop more than 14% today? - MSN
What insider trading reveals about Evogene Ltd. stockMarket Sentiment Report & Fast Gaining Stock Reports - mfd.ru
Will Evogene Ltd. stock benefit from AI adoptionJuly 2025 Retail & Low Drawdown Momentum Ideas - mfd.ru
Evogene Ltd. Expands Google Cloud Collaboration to Integrate AI Agents into ChemPass AI™ - iGrow News
Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases - Finviz
Evogene expands Google Cloud collaboration to enhance AI platform - Investing.com Australia
Evogene announces warrant inducement deal for $3.4 million By Investing.com - Investing.com Australia
Evogene expands Google Cloud collaboration to enhance AI platform By Investing.com - Investing.com Canada
Evogene stock rises as company expands Google Cloud collaboration By Investing.com - Investing.com South Africa
Evogene stock rises as company expands Google Cloud collaboration - Investing.com
Evogene announces warrant inducement deal for $3.4 million - Investing.com Nigeria
Evogene Enters Warrant Inducement Agreement Amid Stock Decline - Intellectia AI
Why Did EVGN Shares Drop More Than 14% Today? - Asianet Newsable
Evogene raises $3.4M by cutting warrant price to $1 each - Stock Titan
Finanzdaten der Evogene Ltd-Aktie (EVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):